-
Mashup Score: 0
Patients with high-risk disease were shown to have a significantly higher mean value of SUVmax compared with patients with low-risk disease (23.5 ± 13.2 vs 10.6 ± 5.4; P < 0.05).
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1Approval sought for TLX007-CDx in prostate cancer - 3 day(s) ago
“If approved by the FDA, this new product will have a significant impact on prostate cancer patients, physicians, and their caregivers by helping to eliminate the inequity of access to PSMA-PET agents, and increase the ability to accurately diagnose cancer early, reducing the cost of care, and increasing the probability of patients’ survival,” says Mike Crosby.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 17
“A unique aspect of AUA guidelines is the robust methodological review,” says Todd M. Morgan, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 4
“When thinking about living with prostate cancer, this is really a couples’ disease, and partners’ unmet needs should be part of the conversation,” says Stacy Loeb, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 4
“When thinking about living with prostate cancer, this is really a couples’ disease, and partners’ unmet needs should be part of the conversation,” says Stacy Loeb, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0Study establishes proof of concept for TLX592 in prostate cancer - 10 day(s) ago
Preliminary results from the CUPID study were based on data from 11 evaluable patients with advanced prostate cancer.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 6
“We were deeply impressed by Galen’s performance in the study, that based on our validation, clearly showed how Ibex can support our clinicians in improving diagnostic quality and efficiency, and as a result we have decided to implement it routinely,” says Junya Fukuoka, MD, PhD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 3
“Prolaris precisely describes the difference in metastasis outcomes for men receiving monotherapy (RT) vs multimodal therapy (RT+ADT), and further tells me precisely what the risk of death is for a man on surveillance,” says Jonathan D. Tward, MD, PhD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1Dosing begins in study of PSMA-targeted therapy in mCRPC - 21 day(s) ago
The phase 2/3 AlphaBreak trial is evaluating the safety and efficacy of FPI-2265 in patients with mCRPC who have been previously treated with 177Lu-PSMA radiotherapy.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1
“Our research shows that the identification of these genetic factors, even in geriatric patients, is important for determining targeted treatment and overall patient survival,” says Mahdi Taha, DO, FACOI, FACP.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
“SUVmax values of intermediate and high-risk patients were significantly higher than those of low-risk patients, supporting the usage of [68Ga]GA-PSMA-11 PET/CT in the initial staging of prostate cancer," concluded the authors. #pcsm #urology https://t.co/gY5Si2ejT1